I was feeling vaguely guilty this week when heading out to a sports complex in suburban Ottawa for my vaccination. As I write this, only 19 percent of Canadians have shared my experience and just before my vaccine day arrived, tens of thousands of vaccination appointments in Manitoba and Ontario were canceled.
pulled slightly ahead of the United States in average daily new cases per capita. Moderna cut deliveries of its vaccine to Canada and other countries while the Johnson & Johnson vaccine, which has yet to arrive in Canada, has come under safety scrutiny.
paused the use of Johnson & Johnson’s one-dose vaccine over concerns that it might be linked to a rare but serious blood-clotting disorder. Canada is expecting its first shipment of that vaccine — 300,000 doses — on April 27.
My colleagues Denise Grady and Carl Zimmer examined the blood-clotting risk potentially posed by that vaccine as well as the AstraZeneca vaccine. Their bottom line: If there is a risk, it’s low.
[Read: J & J Vaccine and Blood Clots: The Risks, if Any, Are Very Low]
But perhaps offsetting all that is Mr. Trudeau’s announcement that Pfizer will sell Canada an additional eight million doses of the vaccine it has developed with BioNTech, half of which will arrive next month, and all of which will arrive by the end of July. The company will also be sending earlier purchases sooner. All that may mean that all Canadian adults will have received at least one shot by July, the prime minister said.